Technology Networks

Regulus Therapeutics



Tel:
Fax:

Print Email to a friend

Regulus Therapeutics is a biopharmaceutical company created to discover, develop and commercialize microRNA therapeutics. Formed as a joint venture between Isis – a pioneer in oligonucleotide drug technologies and a leader in the field of antisense therapeutics, and Alnylam – a leader in the field of RNAi therapeutics, Regulus intends to address therapeutic opportunities that arise from abnormal expression or mutations in microRNAs.

Further Information: http://www.regulusrx.com/


Related news from our archive

Regulus Gains License for IP on Immuno-inflammatory microRNAs from California Institute of Technology
Research demonstrates that microRNA-146 and microRNA-155 are key mediators of immune responses.

Regulus, Alnylam, and Collaborators Publish In Vivo Efficacy Data for a microRNA Therapeutic in a Disease Model
New findings published in the journal Nature demonstrate therapeutic benefit of anti-microRNA-21 in an animal model of heart failure.

Regulus Therapeutics and Collaborators Discover Role of microRNA in Tumor Angiogenesis
New findings highlight role of miR-296 in regulating pathways of angiogenesis and demonstrate potential new applications of microRNA therapeutics in cancer.

Regulus Therapeutics and Collaborators Publish Data on a Critical Role for miR-21 in Brain Tumors
Data demonstrated that miR-21 is responsible for the regulation of multiple genes associated with glioma tumor cell death, migration and invasiveness.

Regulus Gains License for IP on Immuno-inflammatory microRNAs from California Institute of Technology
Research demonstrates that microRNA-146 and microRNA-155 are key mediators of immune responses.

Regulus, Alnylam, and Collaborators Publish In Vivo Efficacy Data for a microRNA Therapeutic in a Disease Model
New findings published in the journal Nature demonstrate therapeutic benefit of anti-microRNA-21 in an animal model of heart failure.

Regulus Therapeutics and Collaborators Discover Role of microRNA in Tumor Angiogenesis
New findings highlight role of miR-296 in regulating pathways of angiogenesis and demonstrate potential new applications of microRNA therapeutics in cancer.

Regulus Therapeutics and Collaborators Publish Data on a Critical Role for miR-21 in Brain Tumors
Data demonstrated that miR-21 is responsible for the regulation of multiple genes associated with glioma tumor cell death, migration and invasiveness.